Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 6;5(3):otad047.
doi: 10.1093/crocol/otad047. eCollection 2023 Jul.

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

Aakash Desai  1 , Jana G Hashash  2 , Gursimran S Kochhar  3 , Francis A Farraye  2
Affiliations

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

Aakash Desai et al. Crohns Colitis 360. .

Abstract

Background: Tixagevimab and cilgavimab (Evusheld) are 2 fully human monoclonal antibodies that received emergency-use authorization on December 21, 2021, for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in patients who are moderate-severely immunocompromised. The real-world efficacy of Evusheld in patients with inflammatory bowel disease (IBD) is not known.

Methods: We conducted a retrospective cohort study using TriNetX, a multi-institutional database in patients with IBD who received Evusheld compared to patients with IBD who did not receive Evusheld (12.1.2021-10.28.2022). The primary outcome was to assess the risk of COVID-19 within 6 months. One-to-one propensity score matching (PSM) was performed for demographic parameters, comorbid conditions, IBD medications, and history of COVID-19. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence interval (CI).

Results: Four hundred and eight patients (0.19%) with IBD received Evusheld (mean age 58.6 ± 15.4 years old, female 47.7%) during the study period. After PSM, there was no difference in the risk (aOR 0.88, 95% CI, 0.33-2.35) of COVID-19 in the Evusheld cohort compared to the IBD control cohort. No patients required ICU care or intubation/respiratory support or were deceased in the Evusheld cohort.

Conclusions: Our study did not show that Evusheld decreases the risk of COVID-19 in patients with IBD. Prevention of moderate-severe COVID-19 in these patients should focus on vaccination strategies and early COVID-19 therapies.

Keywords: COVID-19; cilgavimab; inflammatory bowel disease; tixagevimab.

PubMed Disclaimer

Conflict of interest statement

A.D.: None exists. J.G.H. holds the position of Associate Editor for Crohn’s & Colitis 360 and has been recused from reviewing or making decisions for the manuscript. G.S.K.: Advisor Board: Corvetas Research Foundation, Lilly Pharmaceuticals, GIE medical; Stock options: Digbi Health. F.A.F. is a consultant for BMS, Braintree Labs, GSK, IBD Educational Group, Innovation Pharmaceuticals, Janssen, Pfizer and Sebela. He sits on a DSMB for Adiso Therapeutics and Lilly.

References

    1. Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124 - DOI - PMC - PubMed
    1. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188–2200. doi: 10.1056/nejmoa2116620 - DOI - PMC - PubMed
    1. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. FDA. Published December 8, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...
    1. Nguyen Y, Flahault A, Chavarot N, et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022;28(12):1654.e1–1654.e4. doi: 10.1016/j.cmi.2022.07.015 - DOI - PMC - PubMed
    1. Al-Obaidi MM, Gungor AB, Kurtin SE, Mathias AE, Tanriover B, Zangeneh TT.. The prevention of COVID-19 in high-risk patients using tixagevimab–cilgavimab (Evusheld): Real-world experience at a large academic center. Am J Med. 2022;136(1):96–99. doi: 10.1016/j.amjmed.2022.08.019 - DOI - PMC - PubMed

LinkOut - more resources